Jillian B. Thomsen

Jillian B. Thomsen (senior executive) discloses dealings in Nektar Therapeutics to SEC (Form 4). Over a trading history stretching from 19 January 2016 to 16 February 2023, the count stands at 13 filings.

On the market, this insider has only sold: 7 sales, €448k in total. No amount is published for 2 filings, which the totals therefore leave out. Outside the open market, there are 4 share grants and 2 option exercises. So far in 2023, the count stands at no purchases and 1 sale.

Most recently, on 17 February 2023, the filings show an open-market sale worth €29k in Nektar Therapeutics. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.